Background
==========

Approximately one million people die each year from malaria, mostly African children under the age of five and pregnant women \[[@B1],[@B2]\]. Malaria is, therefore, one of the major global killer diseases and one of the world\'s biggest public health problems \[[@B1],[@B3]\]. As malaria is mainly prevalent in low-income countries, it places a disproportionately heavy economic burden on endemic countries, contributing to poverty and limiting economic development \[[@B1],[@B4]\].

Malaria is a complex disease, which is transmitted to humans through the bite of the female *Anopheles*mosquito inoculating protozoan parasites of the genus *Plasmodium*. There are five types of human malaria, *Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale*, and *Plasmodium knowlesi*, with *P. falciparum*and *P. vivax*being the most common and *P. falciparum*being the most deadly \[[@B1],[@B2]\].

A protective malaria vaccine that prevents or reduces clinical malaria and associated mortality, as well as reducing transmission, will have a major impact on global human health and socioeconomic development. There is considerable optimism that a malaria vaccine can be developed, as immunity developed following natural infection eventually prevents mortality and protects against clinical disease \[[@B3]\].

A malaria vaccine developed by GlaxoSmithKline (GSK) is being tested in various African countries in Phase III clinical trials, following earlier relatively promising results indicating that perhaps 40-50% of immunized children were protected against natural infection for a significant period \[[@B5]\]. However, it seems unlikely that GSK\'s RTS, S pre-erythrocytic stage vaccine will generate higher levels of protection in Phase III clinical trials than those achieved in Phase II clinical trials and it is doubtful whether the RTS, S vaccine will have any impact on reducing malaria transmission. To achieve elimination and eventual eradication, it is clearly necessary to intensify the research and development effort to obtain more protective, longer lasting malaria vaccines, including vaccines which also protect against other species of malaria, particularly the very widely transmitted *P. vivax*.

History of European Commission funded malaria vaccine projects
--------------------------------------------------------------

Under the Fifth Framework Programme (FP) plan for Research and Technology Development (1998-2002), the European Commission (EC) funded a broad range of research activities related to the three major poverty-related diseases (PRDs), HIV/AIDS, malaria and tuberculosis. A total of 24 malaria projects were supported in this period, with a total budget of approximately € 29 million, of which around € 17 million was dedicated to malaria vaccine projects \[[@B1],[@B6]\]. Increased funding for PRD research was provided in FP6 (2002-2006) and a portfolio of 17 malaria projects was established, with an overall budget of about € 64 million, of which almost € 20 million was dedicated to malaria vaccine projects \[[@B1]\].

In the current FP7 plan, (2007-2013), efforts were made to capitalize on the advances achieved under FP6 by improved integration of basic malaria research with more robust research and management structures to translate research results into therapeutic drugs or vaccine candidates. By the end of 2010, halfway through the FP7, a total of nearly € 80 million was earmarked for malaria research. However, only around € 10 million was earmarked for malaria vaccine research \[[@B1]\]. This probably reflected optimism that the GSK RTS, S vaccine would translate well into the developing global anti-malaria campaign and fuelled suggestions that improved vaccines were not a priority.

The past and present EC funded malaria vaccine projects under FP5, FP6 and FP7 are listed in Table [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"} respectively \[[@B1]\].

###### 

Malaria vaccine projects funded by the EC FP5

  Project                                 Project   Coordinator                                                       Partner   EC Contribution   Duration   Start
  --------------------------------------- --------- ----------------------------------------------------------------- --------- ----------------- ---------- ------------
  EUROMALVAC1                             RS        D. Arnot, University of Edinburgh, UK                             10        3 500 000         36         01-02-2000
  ATTMAL                                  RS        A. Waters, Leiden University, NL                                  5         1 492 640         36         01-03-2000
  MALTRANS                                RS        R. Sauerwein, Radboud University Nijmegen Medical Centre, NL      11        2 499 962         36         01-03-2000
  AMVTNETHIC                              AM        S. Jepsen, Statens Serum Institut, DK                             1         220 000           36         01-04-2000
  PAMVAC                                  RS        M. Klinkert, Bernhard-Nocht-Institute for Tropical Medicine, DE   6         1 503 210         36         01-09-2001
  NEMLAR                                  AM        S. Jepsen, Statens Serum Institut, DK                             1         70 000            36         01-12-2001
  EMLI                                    DM        P. Druilhe, Institut Pateur, FR                                   7         1 462 733         36         01-01-2002
  EMVI                                    AM        S. Jepsen, Statens Serum Institut, DK                             2         700 000           36         01-08-2002
  EUROMALVAC2                             RS        D. Arnot, University of Edinburgh, UK                             12        3 700 044         36         01-09-2002
  VIRIMAL                                 RS        P. Preiser, Medical Research Council, UK                          5         1 196 180         36         01-09-2002
  AMVTN/AMANET                            CA        S. Jepsen, Statens Serum Institut, DK                             16        1 000 000         36         01-11-2002
                                                                                                                                                             
  ***Total EC contribution under FP5***             ***17 344 769***                                                                                         

AM: Accompanying Measures, CA: Coordination Action, DM: Demonstration, RS: Research

###### 

Malaria vaccine projects funded by the EC FP6

  Project                                 Project   Coordinator                                                 Partner   EC Contribution   Duration   Start
  --------------------------------------- --------- ----------------------------------------------------------- --------- ----------------- ---------- ------------
  MALINV                                  STREP     L. Rénia, Département d\'Immunologie, Institut Cochin, FR   5         587 000           24         01-06-2005
  SME Malaria                             STREP     R. Glück, Etna Biotech, IT                                  5         1 700 000         36         01-03-2006
  EMVDA                                   IP        O. Leroy, European Vaccine Initiative, DE                   15        13 500 000        63         01-12-2006
  EURHAVAC                                SSA       O. Leroy, European Malaria Vaccine Initiative, DK           1         260 000           24         01-12-2006
  CILMALVAC                               STREP     M. Hartmann, Cilian AG, DE                                  3         1 271 664         36         01-01-2007
  PRIBOMAL                                STREP     J. Goudsmit, Crucell Holland, NL                            7         2 345 358         48         01-02-2007
                                                                                                                                                       
  ***Total EC contribution under FP6***             ***19 664 022***                                                                                   

IP: Integrated Project, SSA: Specific Support Actions, STREP: Specific Targeted Research Project

###### 

Malaria vaccine projects funded by the EC FP7

  Project                                 Project    Coordinator                                                    Partner   EC Contribution   Duration   Start
  --------------------------------------- ---------- -------------------------------------------------------------- --------- ----------------- ---------- ------------
  PreMalStruct                            S/M-SFRP   B. Gamain, Institut Pasteur, FR                                5         2 300 000         36         01-02-2008
  STOPPAM                                 S/M-SFRP   M. Laurent, Institut de Recherche Pour le Development, FR      6         3 000 000         36         01-02-2008
  INYVAX                                  CA         O. Leroy, European Vaccine Initiative, DE                      7         932 335           36         01-02-2009
  OPTIMALVAC                              CA         O. Leroy, European Vaccine Initiative, DE                      12        1 000 000         36         01-04-2009
  REDMAL                                  FRP        R. Sauerwein, Radboud University Nijmegen Medical Centre, NL   6         2 999 998         48         01-03-2010
                                                                                                                                                           
  ***Total EC contribution under FP7***              ***10 232 333***                                                                                      

CA: Coordination Action, S/M-SFRP: Small or medium-scale focused research project

Key successes, their impact and future perspectives
---------------------------------------------------

Vaccines are one of the most effective ways to protect people against infectious diseases, and one of the most cost-effective measures of public health. A malaria vaccine is unlikely to be developed if not supported by public sector and charitable funding and international public organizations, such as the EC \[[@B7]\].

Useful and significant advances have already been achieved by several malaria vaccine projects funded by the EC. A number of its malaria vaccine development projects are in the clinical testing process and will report in the next period. Current EC strategies clearly complement those of other international agencies in this area and have the potential to make a major impact on malaria vaccine development projects. It is, therefore, critical that the EC continues to build on the major advances in understanding immunity to malaria that have been achieved and on several successes in raising immunogenicity of candidate vaccines. Rather than abandon this field, mechanisms for continuing to develop more effective malaria vaccines by building on the current RTS, S successes should be established \[[@B7]\].

Conclusions
===========

To maintain and consolidate the European vaccine development infrastructure and exploit the considerable depth of European expertise in this area, continued funding for malaria vaccine research is essential. Doing otherwise will ensure that European vaccine R&D teams, in both industry and academia, will be forced to disband and Europe risks becoming irrelevant in the global push to eliminate malaria, just as this campaign gathers momentum.
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